| INTRODUCTION
Owing to the development of anti-tumour necrosis factor (TNF) agents, Crohn's disease (CD) treatment has dramatically improved over the last 15 years. However, 30% of patients who receive anti-TNF agents experience primary failure, and 23%-46% of patients experience loss of response or intolerance in the first 12 months of treatment with adalimumab or infliximab. [1] [2] [3] In these situations, it is possible to add immunosuppressors (ISs; such as methotrexate or thiopurine), 4 to escalate the dose, [5] [6] [7] to switch to another anti-TNF agent (adalimumab or infliximab in Europe and certolizumab in the United States) 8 or to change the therapeutic class using anti-a4b7
antibodies, such as vedolizumab, or anti-Il12/23 antibodies, such as ustekinumab. In the meta-analysis by Gisbert et al, switching to another anti-TNF agent due to failure or intolerance was associated with a 43% remission rate and a 63% response rate. This remission rate was greater if the cause of discontinuation was intolerance (61%), compared to loss of response (45%) or primary failure (30%). 9 Moreover, infliximab reintroduction after successive failures of infliximab and adalimumab allowed for a 42% clinical remission rate at 6-8 weeks. 10 The retrospective study by Allez et al showed that a thirdline anti-TNF treatment induced a clinical response rate of 51% at 20 months.
11
Golimumab is a recombinant IgG1 human monoclonal antibody, with high affinity for soluble and membrane-bound TNFa. 12 In the PURSUIT-SC randomised controlled trial, golimumab showed efficacy in patients with moderate-to-severe ulcerative colitis (UC) for both induction and maintenance indications. [13] [14] [15] Although there is no theoretical reason not to use golimumab in CD, it has not been studied for this indication. Nevertheless, some CD patients have already been treated with this molecule, either for associated rheumatologic disease 16, 17 or for CD indications after failure of other available anti-TNF agents. The aim of the current study was to retrospectively assess the safety and efficacy of golimumab in CD.
| PATIENTS AND METHODS

| Patients
Our retrospective study included patients from 12 French tertiary centres. Eligible patients were aged 18 years old or older with established diagnoses of CD, and they were treated with golimumab either for CD or for an associated disease. Patients were excluded if they had quiescent CD at golimumab initiation (golimumab indicated only for associated rheumatologic disease), if golimumab was administered as a postoperative treatment, if fewer than two golimumab administrations were performed or if the follow-up was shorter than 6 weeks. All of the patients provided oral consent to be involved in this study. were performed when appropriate. The probability of remaining on golimumab without escalation or discontinuation was analysed using the Kaplan-Meier method. The log-rank test was used to compare survival curves. Cox proportional hazard models were used to identify predictors of being able to maintain golimumab treatment without escalation or discontinuation. All variables with P < .05 in univariate analysis were included in the multivariate model. A P < .05 was considered statistically significant. The JMP10 (SAS, Cary, NC, USA) software was used for all of the statistical analyses.
| Data collection
3 | RESULTS
| Patient characteristics
A total of 132 CD patients treated with golimumab were recorded.
After exclusion of patients treated for only rheumatologic indications (n = 8) or post-operative indications (n = 7), patients followed up for fewer than 6 weeks after the first golimumab administration (n = 1)
or patients who had only one administration (colonic adenocarcinoma discovery) (n = 1), 115 patients were finally enrolled in this study. Population characteristics are shown in Table 1 . Golimumab was administered as the median third-line biotherapy (first line: n = 1; second line: n = 9; third line: n = 53; fourth line: n = 32;
≥fifth line: n = 21), after 13.5 years of disease evolution. Most of the patients were female and had ileocolonic involvement. Extraintestinal manifestations were very frequent, notably 33% with spondyloarthropathy, compared to the 5% usually expected. 18, 19 The median duration of follow-up was 18.2 months (2.5-44.0).
| Prior anti-TNF treatment
History of previous biologic therapy is presented in Table S1 . The were administered in half of the cases for the first anti-TNF treatment. The most common therapeutic sequence was infliximab, then adalimumab and finally golimumab (32.5% of cases). In all of the patients but 10 (6 with associated rheumatologic diseases), golimumab was used as at least the third anti-TNF agent.
| Golimumab treatment
Information regarding golimumab treatment is indicated in Table 2 .
The probability of remaining on golimumab without escalation or discontinuation at 6, 12 and 24 months was 54.6%, 34.9% and 19.3%, respectively ( Figure 1A) , and the probability of remaining on golimumab without discontinuation at the same time point was 94.6%, was achieved in 27 patients (71%). CRP at golimumab onset was available for 86 patients (74.8%), but follow-up CRP was available in 52 patients (45.2%) only. In these 52 patients, the decrease in CRP between treatment initiation and evaluation was statistically significant (P = .04, Figure S1 ). The dosing schedule for maintenance treatment recommended in UC (50 mg/4 weeks if weight <80 kg; 100 mg/4 weeks if weight >80 kg) was followed in 53% of cases.
When restricting this analysis to patients with available evaluations at between 6 and 14 weeks (n = 53), the response rate was 58.5% (31 patients), and most of the patients who did not achieve clinical response were not escalated (16 patients of 22). Golimumab escalation was undertaken in 44% of cases after 7.9 months of treatment (1.3-34) and for CD indications only. In "escalated" patients, 52.1% were still on golimumab at the end of follow-up, compared to 49.2% in "non-escalated" patients ( Figure S2 ). The rates of golimumab discontinuation were 32.9% and 70.6% at 12 and 24 months respectively ( Figure 1B) . The reasons for discontinuation were primary failure (28 patients, 47%), loss of response (24 patients, 40%) and intolerance (7 patients, 12%).
| Predictive factors
We then looked for predictive factors associated with golimumab efficacy (determined by the duration of golimumab treatment before escalation or discontinuation). In univariate analysis ( 
| Golimumab safety
No serious adverse events (serious infection, death, hypersensitivity)
were reported in our population (Table S2) . One patient stopped treatment for personal reasons and 7 for intolerance: paradoxical psoriasis (n = 3), peripheral paraesthesia that already occurred under adalimumab (n = 1), oedema that already appeared under adalimumab (n = 1) and serious reaction at the injection site (n = 1). In one case, information about the type of intolerance could not be recovered.
| DISCUSSION
Loss of response and intolerance are the two major current issues in CD patients with initial clinical responses to anti-TNF. In clinical practice, patients with successive failure on two CD-approved anti-TNF agents are increasingly frequent. Anti-TNF switching and reintroduction of an anti-TNF previously discontinued, even after two anti-TNF lines, have been shown to be efficient without an increase in adverse events. [8] [9] [10] Although there has been dynamic research into new molecules targeting other disease pathways, escalating treatment with the available anti-TNF agents remains of major importance. In this retrospective study, we analysed the efficacy and safety of golimumab in CD patients.
In our French nationwide cohort of CD patients, golimumab was administered most often after infliximab and adalimumab, which are the only two approved anti-TNF agents for CD (certolizumab is not approved for this indication in France). The clinical response rate was 55.8% after approximately 4 months of treatment, and the probability of remaining on golimumab without escalation at 6 and 12 months was 54.6% and 34.9% respectively. In the study by Allez et al, the probability of remaining on treatment with the third anti-TNF (adalimumab or certolizumab) was 33% at 12 months. In comparison, in our work, the probability of remaining on golimumab was 67.1% at 12 months. 11 In the PURSUIT-M randomised trial performed in UC, the clinical remission rate at 12 months was 47.0% in patients receiving 50 mg every 4 weeks and 49.7% in those receiving 100 mg every 4 weeks. In the same study, it was proposed to evaluate golimumab efficacy at 14 weeks because 15.6% of nonresponders at 6 weeks were responders at 14 weeks. In our population, among the 28 patients classified as primary failures, only 12 received golimumab for more than 14 weeks, suggesting that longer treatment could have achieved a higher response rate.
In the meta-analysis by Peyrin-Biroulet et al, 20 the clinical remission rate at 1 year was 28%-41% for CD patients on adalimumab or infliximab. In our study, the probability of still being on golimumab without escalation at 12 months was 34.9%, despite the included patients being particularly drug resistant, showing that golimumab could have potential benefit in CD.
The two independent predictors of golimumab efficacy were intolerance as the reason for the first anti-TNF discontinuation and concomitant immunosuppression during the first 6 months of golimumab treatment. These results were in accordance with the literature because it has been shown that the efficacy of a second anti-TNF agent in CD patients largely depends on the cause for switching. In this case, the remission rate was higher when the reason to withdraw the first anti-TNF was intolerance. at the time of our study. Their use might also be useful for deciding between using a third anti-TNF agent or switching the mechanism of action, although a proper study is required to specifically address this point.
The safety profile of golimumab was good and was consistent with the results of the PURSUIT trial. 15 No serious adverse events were reported in our study. Of the 7 patients, who had to stop golimumab for intolerance, none of the side effects were life threatening, and 2 of them also occurred with a previously used anti-TNF agent.
Our study had several limitations. It was a retrospective study with a relatively small population. Moreover, it was a reallife study, so there was high heterogeneity between patients and induction and maintenance schemes. Clinical response was based on the HBI or more often on a nonvalidated assessment; however, our primary endpoint (duration of golimumab treatment) was a more objective parameter. Endoscopic data were not available, and CRP values were available in only 80% of cases. However, we believe that our study provides important information in the absence of randomised controlled trials of golimumab in CD.
In conclusion, golimumab was well tolerated in CD and seemed beneficial in half of the patients after anti-TNF failure with infliximab and adalimumab, particularly if administered with concomitant immunosuppression for more than 6 months and if the reason for the first anti-TNF discontinuation was intolerance. A randomised study of golimumab in CD patients would therefore be desirable to confirm our findings. 
